Ask AI
ProCE Banner Activity

Beyond Drug Choice: Optimizing Testing, Sequencing, and Care Pathways for Immunotherapy in Advanced NSCLC

Clinical Thought

In this commentary, disease experts discuss how optimizing clinical processes, including biomarker testing workflows, treatment sequencing, toxicity management, and multidisciplinary coordination, can improve the safe and effective use of immunotherapy for patients with advanced NSCLC.

Released: May 11, 2026

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Merck Sharp & Dohme LLC.

Merck Sharp & Dohme, LLC

Target Audience

This activity is intended for oncologists, nurse practitioners, physician associates, nurses, pharmacists, and other healthcare professionals caring for patients with newly diagnosed advanced/metastatic NSCLC in rural community cancer practices.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify patients with newly diagnosed advanced/metastatic NSCLC at risk for health inequities due to access to care, race/ethnicity, age, or other sociodemographic factors

  • Implement best practices in molecular testing and interpreting results to identify every patient with newly diagnosed advanced/metastatic NSCLC eligible for immunotherapy

  • Collaborate with each patient and the multidisciplinary team to personalize an immunotherapy-based treatment plan for newly diagnosed advanced/metastatic NSCLC with consideration for the latest data, expert recommendations, and patient preferences

  • Educate all eligible patients and their caregivers on the risk–benefit profile and goals of immunotherapy-based treatment using effective communication strategies and resources

  • Manage immune-related adverse events associated with immunotherapy-based treatments to maximize quality of life and clinical outcomes in each patient with newly diagnosed advanced/metastatic NSCLC

Disclosure

Primary Author

Jamie E. Chaft, MD: consultant/advisor/speaker: AstraZeneca, Boehringer Ingelheim, EMD Serono, Exact Sciences, Genentech/Roche, Guardant, Foundation Medicine, Natera, Nuvation Bio, Revolution; researcher (paid to institution): AstraZeneca, BioNtech, Boehringer Ingelheim, Bristol Myers Squibb, Genentech/Roche, Lilly, Merck, Taiho.

Ticiana Leal, MD: consultant/advisor/speaker: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Black Diamond, Catalyst, Gilead, Jazz, Johnson & Johnson, Naterra, Novocure, Nuvation Bio, Pfizer, Roche, Summit Therapeutics, Synthekine, Verastem.